Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Revolution Medicines, Inc. ( RVMD ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Let's get started.

Seeking Alpha • Nov 18, 2025

Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So we'll get started right away.

Seeking Alpha • Nov 11, 2025

Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil

RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.

Zacks Investment Research • Nov 6, 2025

Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Alan Bart Sandler - Chief Development Officer Anthony Mancini Stephen Kelsey - President of Research & Development Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Marc Frahm - TD Cowen, Research Division Leonid Timashev - RBC Capital Markets, Research Division Jenna Li - Jefferies LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Joseph Catanzaro - Mizuho Securities USA LLC, Research Division Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2025 Earnings Conference Call.

Seeking Alpha • Nov 6, 2025

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this year Daraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority Voucher New leadership appointments strengthened global development and commercialization capabilities Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

GlobeNewsWire • Nov 5, 2025

Revolution Medicines to Participate in November 2025 Investor Conferences

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.

GlobeNewsWire • Nov 4, 2025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire • Oct 29, 2025

Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to daraxonrasib, the company's RAS(ON) multi-selective inhibitor, for the treatment of pancreatic cancer.

GlobeNewsWire • Oct 27, 2025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OFF) G12C inhibitor. These results will be highlighted in an oral presentation at the AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Boston, October 23-25.

GlobeNewsWire • Oct 22, 2025